Related Experiment Videos
TP53 overexpression in recurrent endometrial carcinoma
Johanna M A Pijnenborg1, Leonie van de Broek, Geeske C Dam de Veen
1Research Institute Growth and Development (GROW), Department of Obstetrics and Gynecology, University Hospital of Maastricht and University Maastricht, P.O. Box 5800, 6202 AZ Maastricht, Netherlands.
Gynecologic Oncology
|November 8, 2005
Summary
TP53 overexpression predicts recurrent endometrial cancer, independent of p53 mutations. Low hMdm2 and P21 expression indicate a faulty TP53-P21 pathway in recurrent cases.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Endometrioid endometrial carcinoma is a common gynecologic malignancy.
- Recurrence remains a significant challenge in managing early-stage disease.
- The p53 pathway plays a crucial role in tumor suppression and cell cycle regulation.
Purpose of the Study:
- To investigate alterations in the p53 pathway associated with the development of recurrent stage I endometrioid endometrial carcinoma.
- To determine the predictive value of TP53 overexpression and mutations in disease recurrence.
- To explore the relationship between TP53 pathway components (hMdm2, P21) and recurrence.
Main Methods:
- Immunohistochemical analysis of TP53, hMdm2, and P21(Waf1/Cip1) in primary and recurrent tumor tissues.
- Direct sequencing for mutation analysis of p53 (exons 5-8, 11).
- Comparison of protein expression and mutation status between patients with and without recurrence.
Main Results:
- TP53 overexpression was significantly associated with recurrent disease (Odds Ratio 3.8).
- Overexpression of TP53 correlated with lower hMdm2 and P21 expression in recurrent tumors.
- p53 mutations were identified in a minority of cases, with no strong correlation to TP53 overexpression or recurrence.
Conclusions:
- TP53 overexpression is a significant predictor of recurrent endometrial carcinoma.
- The p53 pathway appears dysfunctional in recurrent disease, characterized by TP53 overexpression and reduced P21 expression, often independent of p53 mutations.
- These findings highlight the potential of targeting the TP53-P21 axis for managing recurrent endometrial cancer.